Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 584


Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial.

Rubini Giménez M, Miller PE, Alviar CL, van Diepen S, Granger CB, Montalescot G, Windecker S, Maier L, Serpytis P, Serpytis R, Oldroyd KG, Noc M, Fuernau G, Huber K, Sandri M, de Waha-Thiele S, Schneider S, Ouarrak T, Zeymer U, Desch S, Thiele H.

J Clin Med. 2020 Mar 20;9(3). pii: E860. doi: 10.3390/jcm9030860.


Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock: A Substudy of the CULPRIT-SHOCK Trial.

Rubini Gimenez M, Zeymer U, Desch S, de Waha-Thiele S, Ouarrak T, Poess J, Meyer-Saraei R, Schneider S, Fuernau G, Stepinska J, Huber K, Windecker S, Montalescot G, Savonitto S, Jeger RV, Thiele H.

Circ Cardiovasc Interv. 2020 Mar;13(3):e008537. doi: 10.1161/CIRCINTERVENTIONS.119.008537. Epub 2020 Mar 10.


Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.

Hulot JS, Chevalier B, Belle L, Cayla G, Khalife K, Funck F, Berthier R, Piot C, Tafflet M, Montalescot G; GIANT Investigators.

JACC Cardiovasc Interv. 2020 Mar 9;13(5):621-630. doi: 10.1016/j.jcin.2020.01.219.


Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Guedeney P, Mesnier J, Sorrentino S, Abcha F, Zeitouni M, Lattuca B, Silvain J, De Rosa S, Indolfi C, Collet JP, Kerneis M, Montalescot G.

J Clin Med. 2020 Mar 3;9(3). pii: E680. doi: 10.3390/jcm9030680. Review.


Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation.

Guedeney P, Huchet F, Manigold T, Overtchouk P, Rouanet S, Balagny P, Leprince P, Lebreton G, Letocart V, Barthelemy O, Vicaut E, Montalescot G, Guerin P, Collet JP; ACTION Study Group.

Arch Cardiovasc Dis. 2020 Feb 27. pii: S1875-2136(20)30033-4. doi: 10.1016/j.acvd.2019.12.008. [Epub ahead of print]


Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.

Puymirat E, Simon T, de Bruyne B, Montalescot G, Steg G, Cayla G, Durand-Zaleski I, Blanchard D, Danchin N, Chatellier G; FLOWER-MI study investigators.

Am Heart J. 2020 Apr;222:1-7. doi: 10.1016/j.ahj.2019.12.015. Epub 2019 Dec 27.


Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C, Gonzalez-Juanatey JR, James S, Lopes RD, Mehran R, Montalescot G, Patel M, Steg PG, Storey RF, Vranckx P, Weitz JI, Welsh R, Zeymer U, Angiolillo DJ.

Nat Rev Cardiol. 2020 Apr;17(4):242-257. doi: 10.1038/s41569-019-0314-y. Epub 2020 Jan 17. Review.


Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.

Tomaniak M, Chichareon P, Klimczak-Tomaniak D, Takahashi K, Kogame N, Modolo R, Wang R, Ono M, Hara H, Gao C, Kawashima H, Rademaker-Havinga T, Garg S, Curzen N, Haude M, Kochman J, Gori T, Montalescot G, Angiolillo DJ, Capodanno D, Storey RF, Hamm C, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW, Anderson R.

Clin Res Cardiol. 2020 Jan 10. doi: 10.1007/s00392-019-01586-9. [Epub ahead of print]


GLOBAL LEADERS: looking now at the bigger picture.

Guedeney P, Montalescot G.

EuroIntervention. 2019 Dec 20;15(12):e1030-e1032. doi: 10.4244/EIJV15I12A192. No abstract available.


Do we need a new P2Y12 receptor antagonist?

Hulot JS, Montalescot G.

Eur Heart J. 2019 Dec 17. pii: ehz862. doi: 10.1093/eurheartj/ehz862. [Epub ahead of print] No abstract available.


Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation.

Guedeney P, Huchet F, Manigold T, Rouanet S, Balagny P, Leprince P, Lebreton G, Letocart V, Barthelemy O, Vicaut E, Montalescot G, Guerin P, Collet JP; ACTION Study Group.

Arch Cardiovasc Dis. 2019 Dec;112(12):765-772. doi: 10.1016/j.acvd.2019.09.008. Epub 2019 Nov 20.


Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper.

Bernat I, Aminian A, Pancholy S, Mamas M, Gaudino M, Nolan J, Gilchrist IC, Saito S, Hahalis GN, Ziakas A, Louvard Y, Montalescot G, Sgueglia GA, van Leeuwen MAH, Babunashvili AM, Valgimigli M, Rao SV, Bertrand OF; RAO International Group.

JACC Cardiovasc Interv. 2019 Nov 25;12(22):2235-2246. doi: 10.1016/j.jcin.2019.07.043. Review.


Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.

Tavenier AH, Hermanides RS, Fabris E, Lapostolle F, Silvain J, Ten Berg JM, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Ecollan P, Collet JP, Willems FF, Diallo A, Vicaut E, Hamm CW, Montalescot G, van 't Hof AWJ; ATLANTIC investigators.

Thromb Haemost. 2020 Jan;120(1):65-74. doi: 10.1055/s-0039-1700546. Epub 2019 Nov 21.


Coronary artery disease in systemic lupus: A case-controlled angiographic study.

Chazal T, Kerneis M, Guedeney P, Haroche J, Mathian A, Rufat P, Cohen Aubart F, Montalescot G, Amoura Z.

Autoimmun Rev. 2020 Jan;19(1):102427. doi: 10.1016/j.autrev.2019.102427. Epub 2019 Nov 14. No abstract available.


Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France.

Guedeney P, Aboyans V, Dalon F, Oksen D, Belhassen M, Nolin M, Briere JB, Van Ganse E, Montalescot G.

Arch Cardiovasc Dis. 2019 Nov;112(11):670-679. doi: 10.1016/j.acvd.2019.05.009. Epub 2019 Nov 8.


Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.

Lattuca B, Silvain J, Yan Y, Pouillot C, Cuisset T, Cayla G, Henry P, Diallo A, Elhadad S, Rangé G, Lhermusier T, Boueri Z, Motreff P, Carrié D, Vicaut E, Montalescot G, Collet JP.

Circ Cardiovasc Interv. 2019 Nov;12(11):e007749. doi: 10.1161/CIRCINTERVENTIONS.118.007749. Epub 2019 Nov 7.


On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention.

Lattuca B, Kerneis M, Saib A, Nguyen LS, Payot L, Barthélemy O, Le Feuvre C, Helft G, Choussat R, Collet JP, Montalescot G, Silvain J; ACTION Study Group.

JACC Cardiovasc Interv. 2019 Nov 25;12(22):2260-2268. doi: 10.1016/j.jcin.2019.07.017. Epub 2019 Oct 30.


Predictors of Left Ventricular Dysfunction in Friedreich's Ataxia in a 16-Year Observational Study.

Legrand L, Diallo A, Monin ML, Ewenczyk C, Charles P, Isnard R, Vicaut E, Montalescot G, Durr A, Pousset F.

Am J Cardiovasc Drugs. 2020 Apr;20(2):209-216. doi: 10.1007/s40256-019-00375-z.


Aspirin-Free Strategies After PCI: Still Not Out of the Twilight.

Collet JP, Montalescot G, Zeitouni M.

J Am Coll Cardiol. 2019 Oct 22;74(16):2028-2031. doi: 10.1016/j.jacc.2019.08.998. No abstract available.


Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial.

Zeitouni M, Barthélémy O, Hauguel-Moreau M, Guedeney P, Rouanet S, Hage G, Overtchouk P, Brugier D, Vignolles N, Kerneis M, Silvain J, Collet JP, Vicaut E, Desch S, Zeymer U, Thiele H, Montalescot G.

Circ Cardiovasc Interv. 2019 Oct;12(10):e008296. doi: 10.1161/CIRCINTERVENTIONS.119.008296. Epub 2019 Oct 14. No abstract available.


Long-Term Evolution of Premature Coronary Artery Disease.

Collet JP, Zeitouni M, Procopi N, Hulot JS, Silvain J, Kerneis M, Thomas D, Lattuca B, Barthelemy O, Lavie-Badie Y, Esteve JB, Payot L, Brugier D, Lopes I, Diallo A, Vicaut E, Montalescot G; ACTION Study Group.

J Am Coll Cardiol. 2019 Oct 15;74(15):1868-1878. doi: 10.1016/j.jacc.2019.08.1002.


Modulation of cholesterol efflux capacity in patients with myocardial infarction.

Silvain J, Kerneis M, Guerin M, Montalescot G.

Curr Opin Cardiol. 2019 Nov;34(6):714-720. doi: 10.1097/HCO.0000000000000677.


Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review.

Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ.

J Am Coll Cardiol. 2019 Jul 9;74(1):83-99. doi: 10.1016/j.jacc.2019.05.016. Review.


Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.

Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, Vogel B, Sartori S, De Rosa S, Baber U, Indolfi C, Montalescot G, Dangas GD, Rosenson RS, Pocock SJ, Mehran R.

Eur Heart J. 2019 Jul 3. pii: ehz430. doi: 10.1093/eurheartj/ehz430. [Epub ahead of print]


Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment.

Bergmeijer TO, van Oevelen M, Janssen PWA, Godschalk TC, Lichtveld RA, Kelder JC, Voskuil M, Mosterd A, Montalescot G, Ten Berg JM.

TH Open. 2018 Oct 11;2(4):e357-e368. doi: 10.1055/s-0038-1673389. eCollection 2018 Oct.


Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.

Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Röther J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators.

J Am Coll Cardiol. 2019 Jul 2;73(25):3281-3291. doi: 10.1016/j.jacc.2019.04.046.


Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial.

Montalescot G, Brotons C, Cosyns B, Crijns HJ, D'Angelo A, Drouet L, Eberli F, Lane DA, Besse B, Chan A, Vicaut E, Darius H; AEGEAN Study Investigators.

Am J Cardiovasc Drugs. 2020 Feb;20(1):61-71. doi: 10.1007/s40256-019-00356-2.


Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.

Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):200-206. doi: 10.1093/ehjcvp/pvz020.


P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.

Povsic TJ, Ohman EM, Roe MT, White J, Rockhold FW, Montalescot G, Cornel JH, Nicolau JC, Steg PG, James S, Bode C, Welsh RC, Plotnikov AN, Mundl H, Gibson CM.

JAMA Cardiol. 2019 Jul 1;4(7):680-684. doi: 10.1001/jamacardio.2019.1510.


Major Adverse Events With Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation.

Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Gras D, Mansourati J, Deharo JC, Montalescot G, Defaye P.

J Am Coll Cardiol. 2019 May 28;73(20):2638-2640. doi: 10.1016/j.jacc.2019.03.468. No abstract available.


Left Atrial Appendage Closure: Only a Question of Bleeding!

Montalescot G, Guedeney P.

JACC Cardiovasc Interv. 2019 Jun 10;12(11):1077-1079. doi: 10.1016/j.jcin.2018.11.034. Epub 2019 May 15. No abstract available.


Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention.

Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, Farhan S, Vogel B, Sartori S, Montalescot G, Sweeny J, Kovacic JC, Krishnan P, Barman N, Dangas G, Kini A, Baber U, Sharma S, Mehran R.

J Am Coll Cardiol. 2019 May 21;73(19):2401-2409. doi: 10.1016/j.jacc.2019.01.077. Erratum in: J Am Coll Cardiol. 2019 Jul 23;74(3):481-482.


Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: Results from the ATLANTIC study.

Bauer T, Zeymer U, Diallo A, Vicaut E, Bolognese L, Cequier A, Huber K, Montalescot G, Hamm CW, Van't Hof AW; ATLANTIC Investigators.

Catheter Cardiovasc Interv. 2020 Feb 15;95(3):494-500. doi: 10.1002/ccd.28318. Epub 2019 May 8.


Cardiovascular manifestations of sickle cell disease.

Hammoudi N, Lionnet F, Redheuil A, Montalescot G.

Eur Heart J. 2020 Apr 1;41(13):1365-1373. doi: 10.1093/eurheartj/ehz217.


Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach.

Lattuca B, Kerneis M, Zeitouni M, Cayla G, Guedeney P, Collet JP, Montalescot G, Silvain J.

Drugs Aging. 2019 Jun;36(6):531-539. doi: 10.1007/s40266-019-00663-y. Review.


Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Jun;212:13-22. doi: 10.1016/j.ahj.2019.02.006. Epub 2019 Mar 1.


Kidney in the transformation matrix.

Kerneis M, Silvain J, Montalescot G.

Eur Heart J. 2019 Apr 14;40(15):1233-1235. doi: 10.1093/eurheartj/ehz088. No abstract available.


Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.

Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.


Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet JP, Montalescot G, Silvain J.

Am J Cardiovasc Drugs. 2019 Oct;19(5):431-438. doi: 10.1007/s40256-019-00338-4. Review.


Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.

Silvain J, Rakowski T, Lattuca B, Liu Z, Bolognese L, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimsky P, Miller D, Portal JJ, Collet JP, Vicaut E, Montalescot G, Dudek D; ACCOAST Investigators.

J Am Coll Cardiol. 2019 Mar 5;73(8):906-914. doi: 10.1016/j.jacc.2018.11.055.


Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome.

Montalescot G, Angiolillo DJ.

J Am Coll Cardiol. 2019 Feb 26;73(7):775-778. doi: 10.1016/j.jacc.2018.12.022. No abstract available.


Interventional Standby for CABG Surgery: The Reverse Paradigm.

Guedeney P, Montalescot G.

J Am Coll Cardiol. 2019 Feb 5;73(4):424-426. doi: 10.1016/j.jacc.2018.11.023. No abstract available.


Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention.

Nguyen LS, Spagnoli V, Kerneis M, Hauguel-Moreau M, Barthélémy O, Collet JP, Montalescot G, Silvain J.

Arch Cardiovasc Dis. 2019 Mar;112(3):180-186. doi: 10.1016/j.acvd.2018.11.006. Epub 2019 Jan 9.


The false illusion of coronary thrombus device-management.

Lattuca B, Montalescot G.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4117-S4121. doi: 10.21037/jtd.2018.10.25. No abstract available.


Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals.

Hyafil F, Chequer R, Sorbets E, Estellat C, Ducrocq G, Rouzet F, Alfaiate T, Regaieg H, Abtan J, Leygnac S, Milliner M, Imbert L, Burg S, Ben Azzouna R, Potier L, Laouénan C, Quintin C, Roussel R, Hartemann A, Montalescot G, Marie PY, Steg G, Le Guludec D.

J Nucl Cardiol. 2018 Dec 20. doi: 10.1007/s12350-018-01557-z. [Epub ahead of print]


A farewell to aspirin in primary prevention?

Montalescot G.

Nat Rev Cardiol. 2019 Feb;16(2):76-77. doi: 10.1038/s41569-018-0148-z. Review. No abstract available.


Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction.

Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, Hauguel-Moreau M, Zeitouni M, Kerneis M, Lattuca B, Brugier D, Collet JP, Lesnik P, Montalescot G.

J Am Coll Cardiol. 2018 Dec 25;72(25):3259-3269. doi: 10.1016/j.jacc.2018.09.080.


Left Atrial Appendage Closure in Atrial Fibrillation.

Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Gras D, Mansourati J, Deharo JC, Montalescot G, Defaye P.

J Am Coll Cardiol. 2018 Dec 4;72(22):2806-2807. doi: 10.1016/j.jacc.2018.08.2196. No abstract available.


Coronary Artery Bypass Graft Surgery Guided by FFR: Fraction of the Final Response.

Montalescot G, Lattuca B.

J Am Coll Cardiol. 2018 Dec 4;72(22):2744-2746. doi: 10.1016/j.jacc.2018.09.036. No abstract available.


One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy.

Danchin N, Puymirat E, Cayla G, Cottin Y, Coste P, Gilard M, Goldstein P, Braun F, Belle L, Montalescot G, Ferrières J, Schiele F, Simon T; FAST-MI Investigators.

Circ Cardiovasc Interv. 2018 Sep;11(9):e007241. doi: 10.1161/CIRCINTERVENTIONS.118.007241.


Supplemental Content

Loading ...
Support Center